PMID- 11521223
OWN - NLM
STAT- MEDLINE
DCOM- 20010927
LR  - 20171116
IS  - 0046-8177 (Print)
IS  - 0046-8177 (Linking)
VI  - 32
IP  - 8
DP  - 2001 Aug
TI  - Expression of dendritic cells in ovarian tumors correlates with clinical outcome 
      in patients with ovarian cancer.
PG  - 803-7
AB  - Dendritic cells (DCs) are the most potent antigen-presenting cells and are 
      thought to reflect the interaction between the host immune system and tumor 
      cells. In a retrospective study, we analyzed the presence of DCs and memory 
      lymphocytes in tumor biopsy specimens of 18 patients with ovarian cancer. These 
      patients were followed up for 10 to 37 months. Within this period, 9 patients had 
      no evidence of disease (NED, group A), and 9 patients had recurrence (group B). 
      In group A, 5 cases were stage III, 1 was stage I, and 1 was stage II. In group 
      B, 5 cases were stage III, 1 was stage III-IV, and 3 were stage IV. Our results 
      show that the mean number of cells expressing the DC phenotype, HLA-DR(+) 
      CD1a(+), in tumor biopsies was substantially higher in group A than in group B 
      (HLA-DR(+): 37.8 +/- 18.2 v. 10.7 +/- 2.2, respectively; P <.005; CD1a(+): 9.5 
      +/- 11.3 v 2.1 +/- 3.7). On the other hand, the number of cells expressing the DC 
      phenotype S-100 protein was substantially lower in group A than in group B 
      (S-100(+): 9.7 +/- 9.9 v 16.2 +/- 12.7), although the difference was not 
      statistically significant. There was no difference in the number of 
      tumor-infiltrating CD45RO(+) cells between groups A and B (CD45RO(+): 39.1 +/- 
      28.5 v 34.2 +/- 19.1). Our results show that the presence of relatively high 
      numbers of defined DC subpopulations may have prognostic value in ovarian tumors.
FAU - Eisenthal, A
AU  - Eisenthal A
AD  - Pathology Institute, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
FAU - Polyvkin, N
AU  - Polyvkin N
FAU - Bramante-Schreiber, L
AU  - Bramante-Schreiber L
FAU - Misonznik, F
AU  - Misonznik F
FAU - Hassner, A
AU  - Hassner A
FAU - Lifschitz-Mercer, B
AU  - Lifschitz-Mercer B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (Antigens, CD1)
RN  - 0 (CD1a antigen)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (S100 Proteins)
RN  - EC 3.1.3.48 (Leukocyte Common Antigens)
SB  - IM
MH  - Adenocarcinoma/chemistry/immunology/*pathology
MH  - Adult
MH  - Aged
MH  - Antigens, CD1/analysis
MH  - Dendritic Cells/chemistry/*pathology
MH  - Female
MH  - HLA-DR Antigens/analysis
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Immunologic Memory
MH  - Leukocyte Common Antigens/analysis
MH  - Lymphocytes, Tumor-Infiltrating/immunology
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Neoplasm Staging
MH  - Ovarian Neoplasms/chemistry/immunology/*pathology
MH  - Prognosis
MH  - Retrospective Studies
MH  - S100 Proteins/analysis
MH  - T-Lymphocyte Subsets/immunology
EDAT- 2001/08/25 10:00
MHDA- 2001/09/28 10:01
CRDT- 2001/08/25 10:00
PHST- 2001/08/25 10:00 [pubmed]
PHST- 2001/09/28 10:01 [medline]
PHST- 2001/08/25 10:00 [entrez]
AID - S0046-8177(01)63625-6 [pii]
AID - 10.1053/hupa.2001.26455 [doi]
PST - ppublish
SO  - Hum Pathol. 2001 Aug;32(8):803-7. doi: 10.1053/hupa.2001.26455.